Cargando…
New Horizons in Metastatic Colorectal Cancer: Prognostic Role of CD44 Expression
SIMPLE SUMMARY: In our study, we analyzed the role of CD44 expression as a prognostic marker in patients with metastatic colorectal cancer. CD44 is a multi-structural and multifunctional non-kinase transmembrane glycoprotein. Its expression is recognized as a molecular marker of cancer stem cells. D...
Autores principales: | Ziranu, Pina, Aimola, Valentina, Pretta, Andrea, Dubois, Marco, Murru, Raffaele, Liscia, Nicole, Cau, Flaviana, Persano, Mara, Deias, Giulia, Palmas, Enrico, Loi, Francesco, Migliari, Marco, Pusceddu, Valeria, Puzzoni, Marco, Lai, Eleonora, Cascinu, Stefano, Faa, Gavino, Scartozzi, Mario |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953769/ https://www.ncbi.nlm.nih.gov/pubmed/36831554 http://dx.doi.org/10.3390/cancers15041212 |
Ejemplares similares
-
CDX-2 expression correlates with clinical outcomes in MSI-H metastatic colorectal cancer patients receiving immune checkpoint inhibitors
por: Ziranu, Pina, et al.
Publicado: (2023) -
Immune Checkpoint Inhibitors in the Treatment of HCC
por: Donisi, Clelia, et al.
Publicado: (2021) -
Hepatocellular carcinoma and microbiota: Implications for clinical management and treatment
por: Spanu, Dario, et al.
Publicado: (2022) -
How to improve metastatic pancreatic ductal adenocarcinoma patients’ selection: Between clinical trials and the real-world
por: Pretta, Andrea, et al.
Publicado: (2022) -
The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment
por: Ziranu, Pina, et al.
Publicado: (2021)